Anti-LINGO-1: All You Need to Know

admin avatar

by admin |

Share this article:

Share article via email


Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here.

So what is Anti-LINGO-1?

According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently being tested in people with optic neuritis, relapsing-remitting MS, and secondary progressive MS.

LINGO is a protein found in nerve cells and myelin-making cells called oligodendrocytes. Blocking the activity of this protein with an antibody called anti-LINGO-1 has been shown to result in myelin repair in animal models of MS.

Anti-LINGO-1 it’s taken as an intravenous infusion.

Read the Anti-LINGO-1 latest news here:


Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here